Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. - Wikidata - awgldk - TriplyDB

Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.

Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.

http://www.wikidata.org/entity/Q30379095

about

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro Clinical Implications of Antiviral Resistance in Influenza Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead Replication-competent fluorescent-expressing influenza B virus Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses Model-based simulation and prediction of an antiviral strategy against influenza A infection.New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.How I treat influenza in patients with hematologic malignancies.Oseltamivir in human avian influenza infection.Novel (pandemic) influenza A H1N1 in healthcare facilities: implications for prevention and control.Methods for molecular surveillance of influenza.Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.Drugs in development for influenza.The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients.ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Combination chemotherapy for influenza.Epidemiological analysis of critically ill adult patients with pandemic influenza A(H1N1) in South Korea.Newer influenza antivirals, biotherapeutics and combinations.Genome rearrangement of influenza virus for anti-viral drug screening Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model How to approach and treat viral infections in ICU patients Replication-competent influenza A viruses expressing a red fluorescent protein.Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics Severe influenza treatment guideline.Influenza pharmacotherapy: present situation, strategies and hopes.Drugs to cure avian influenza infection--multiple ways to prevent cell death Detection and management of antiviral resistance for influenza viruses.A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action.Molecular analysis of amantadine-resistant influenza A (H1N1 pdm09) virus isolated from slum dwellers of Dhaka, Bangladesh.Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor.A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling

P2860

Q21142648-81750527-66F6-42B8-84AF-0029F8762A98 Q26782746-73073770-9DDC-469D-98ED-C81BAF71CD90 Q26853131-CC308FED-1AC5-4B50-A5BB-BECDC9E676D5 Q27679309-131920DF-8290-409C-8B1E-4477D921613B Q28382972-52FC24E6-A0A4-4AFE-AC96-25A8C24AC4A4 Q28387786-A37EBE5D-0F65-4B5C-AF6A-FE8FB52FB578 Q28478637-D4AAE78C-BCD1-46DF-85CB-E7CD5E21CCDD Q28479036-396FB7C3-E0A0-4012-B9EC-7AF45A8E4A2B Q30352246-CDA43488-F3BB-4138-89C0-13B8E793AE34 Q30355297-1AB9440B-D760-4DD5-BC74-1A0FDBD3974C Q30356466-287A1243-BB43-4C3A-A3C3-ED322734CF24 Q30383456-5B947E7B-4095-431A-AF80-498C0034A41D Q30386487-C42E9666-B47F-4AC5-91E2-7B4C32265DFD Q30387212-F798440E-9E94-4E29-92AA-B52EDA5BA1F2 Q30388975-C2CFC500-19AC-42BB-A5FD-290FE5C11B98 Q30390856-97ED3AC2-3F82-4513-A68E-DB26D7D88243 Q30391218-6A05336F-E3CB-4896-88FE-520C6ECB3CBB Q30397216-052447E4-ED2D-4138-A9AB-B8EE69FFF4F2 Q30398935-EE286FEA-B5A7-4BE4-AC82-8D66599B5DE3 Q30400403-B2F3490D-4744-4AD8-9AFE-346D92B85AFB Q30401587-9B65E782-B726-4335-9922-40B40DFCBD74 Q30404586-1D34F9BE-0F81-44E6-B157-EACEA8E3765A Q30408112-76B57DF2-0DD9-46CB-BCAD-3FF5E735BA5D Q30419932-D706E40C-8FD6-4C2B-B992-FA0FCFAC3AE8 Q30456363-1B79DA1E-EEE6-4352-BA4D-957E62CE133B Q34053717-9E912B74-4BE2-4475-AA82-BC8F9CCB5373 Q34159076-2243ACD3-1712-491E-859C-D8E404210634 Q34737693-C6EA6D34-0B9C-4B25-83F7-839AD8738406 Q34894660-62260ADB-5962-443E-8F1B-7B670CEBB6E0 Q35071285-C1EB8C31-BDDF-4FE6-B3A6-962F8948ECB1 Q35270303-7C06480D-8E71-40F4-B01D-4611854A3D8A Q37549382-E4D10EA2-1433-4DA7-9297-E3A3EC8FD653 Q37598807-0AEE0375-810E-4455-B317-468FE34C3AEC Q37857854-2A5546F2-5797-4F93-9AF8-2C2D864B6E12 Q38148960-EDFBE518-6CFF-4E4E-B16E-E32A4CC1AD52 Q38161553-6318B877-2432-4F49-A634-A32811D7D0A7 Q38802959-384050E6-E8EF-458E-B0F0-F9F82124BBAD Q38841198-79283C6C-EC13-454D-B786-6AC72D3BEFAF Q40874583-6F08470D-49C7-40F2-A2B5-E5087ECE9189 Q41745036-2CF0BB78-56D6-4A8B-8E0D-2C427E353DD8

P2860

Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.

http://www.wikidata.org/entity/Q30379095

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Triple combination of oseltami ...... luenza virus strains in vitro.

@ast

Triple combination of oseltami ...... luenza virus strains in vitro.

@en

type

label

Triple combination of oseltami ...... luenza virus strains in vitro.

@ast

Triple combination of oseltami ...... luenza virus strains in vitro.

@en

prefLabel

Triple combination of oseltami ...... luenza virus strains in vitro.

@ast

Triple combination of oseltami ...... luenza virus strains in vitro.

@en

P1433

Q30379095-36D75E82-95FF-4D6C-896F-47EE49CA807F

P1476

Q30379095-63DE474B-F54E-479E-9CDB-2BC0E4A7A0B0

P2093

Q30379095-050C247A-9A44-472E-ABA4-09B9BD9DE882

Q30379095-3AC8668B-FC91-46AB-A4B1-1D5DB7714EF5

Q30379095-49381ED7-368B-4AC3-81F9-D23F232A70B5

Q30379095-64F976A3-527E-46D3-9093-497DC12C8E9F

Q30379095-7EFC1050-503A-4232-BC61-C4CF8932845A

Q30379095-A2B2F26C-A610-4B24-9C8B-1AEB425037A9

Q30379095-A4D150AC-2FF9-4DB0-94C0-3ADCA557EA98

Q30379095-F06B31A9-680B-4AF6-9E53-0144B696A4A6

Q30379095-F9B052AA-C5BD-4221-94B4-A9896A9171E0

P2860

Q30379095-04C2D0CE-5431-4378-9BAC-05764C49D17F

Q30379095-04CCB616-860C-4DBA-885B-1DD326F219AD

Q30379095-12DF5A44-0BCB-4D31-A3A8-4D51ADA0F893

Q30379095-147712D0-3FEF-4CE0-8FCE-293F496674EF

Q30379095-165B6882-A036-4A0F-9F85-4C309EE3F3A5

Q30379095-1D03F169-F5DB-462B-9136-75B4501690C3

Q30379095-1E9B3931-ADFC-4560-BC2D-464EA43AD518

Q30379095-2D9676EF-2284-44F8-A531-1BE3FC6AEE8C

Q30379095-38972807-33E3-455E-A9B8-FC7C1D43E22C

Q30379095-3C022CE9-8BDA-4C93-A743-17BD6672C766

P304

Q30379095-2ADD58A1-3F42-4DC4-A235-3FF59A07A55D

P31

Q30379095-B85B0015-2027-4943-9CD2-C124A617D5E3

P356

Q30379095-CCBF8FBD-A573-4AF9-B655-6FC18C21E533

P407

Q30379095-58031988-454B-44B4-A59A-589286D7B6A1

P433

Q30379095-60AE8905-882F-441F-97D0-73ED9CF55885

P478

Q30379095-51A6236B-00B3-4924-9FE6-DA3BAF2B84B9

P50

Q30379095-71706763-D96A-49AB-90A7-ABBB3DBC71EC

P577

Q30379095-0AF8B787-0B1C-4CA8-81D8-92D68FE01A15

P698

Q30379095-9D6F691B-58C5-4193-A567-ECD5132AC729

P932

Q30379095-FD082100-B5BB-44BC-8D5E-38518636D000

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Triple combination of oseltami ...... luenza virus strains in vitro.

@en

P2093

David M Engelthaler

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Driebe

http://www.w3.org/2001/XMLSchema#string

Gregory T Went

http://www.w3.org/2001/XMLSchema#string

Jack T Nguyen

http://www.w3.org/2001/XMLSchema#string

Justin D Hoopes

http://www.w3.org/2001/XMLSchema#string

Mark N Prichard

http://www.w3.org/2001/XMLSchema#string

Minh H Le

http://www.w3.org/2001/XMLSchema#string

Paul S Keim

http://www.w3.org/2001/XMLSchema#string

R Paul Spence

http://www.w3.org/2001/XMLSchema#string

P2860

Amantadine and rimantadine for influenza A in adults

Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells

Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia

Update on avian influenza A (H5N1) virus infection in humans

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities

Enhancement of activity against influenza viruses by combinations of antiviral agents

Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.

A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination

P304

4115-4126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00476-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19620324

http://www.w3.org/2001/XMLSchema#string

P932

2764153

http://www.w3.org/2001/XMLSchema#string